Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.
Atlassian’s Strategic Loom Acquisition Could Be A Game-Changer for Collaborative Workflows, Analysts Say
Canaccord Genuity analyst David Hynes Jr reiterated a Buy rating on Atlassian Corp (NASDAQ: TEAM) with a
